肛褶蛙肽 | 63968-82-1

• 物质功能分类: 生物化工 - 多肽
• 分子结构分类: 有机化合物 - 有机聚合物 - 多肽
• 中文名称: 肛褶蛙肽
• 英文名称: L-alpha-Aspartyl-L-valyl-L-prolyl-L-lysyl-L-seryl-L-alpha-aspartyl-L-glutaminyl-L-phenylalanyl-L-valylglycyl-L-leucyl-L-methioninamide
• 英文别名: (3S)-3-amino-4-[[(2S)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
• CAS: 63968-82-1
• 化学式: C₅₉H₉₅N₁₅O₁₈S
• 分子量: 1334.5
• InChiKey: NXTPETCPVNEEOP-FJCMUPJRSA-N

物化性质

• 密度：
  1.305
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  -7.5
• 重原子数：
  93
• 可旋转键数：
  43
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  570
• 氢给体数：
  17
• 氢受体数：
  21

制备方法与用途

生物活性

Kassinin 是一种从非洲蛙 Kassina senegalensis 皮肤中衍生出来的肽。它属于速激肽家族的神经肽，主要通过分泌作为防御信号，并参与神经肽信号传导。

体外研究

Kassinin 是一种十二肽 tachykinin 类多肽，来源于非洲蟾蜍 Kassina senegalensis 的皮肤提取物。该多肽具有典型的 C-末端三肽 Gly-Leu-Met-NH2 和位于 C-末端第 5 位的苯丙氨酸残基。与其它天然速激肽不同的是，其 N 端氨基酸序列有显著差异。

文献信息

• PERIODONTAL DISEASE STRATIFICATION AND USES THEREOF
  申请人：The University of North Carolina at Chapel Hill

  公开号：US20200187851A1

  公开（公告）日：2020-06-18

  Described herein are methods of classifying periodontal patients and individual teeth. For example, disclosed is a method of diagnosing periodontal disease and/or risk of tooth loss in a subject that involves classifying teeth into one of 7 classes of periodontal disease. The method can include the step of performing a dental examination on a patient and determining a periodontal profile class (PPC). The method can further include the step of determining for each tooth a Tooth Profile Class (TPC). The PPC and TPC can be used together to generate a composite risk score for an individual, which is referred to herein as the Index of Periodontal Risk (IPR). In some embodiments, each stage of the disclosed PPC system is characterized by unique single nucleotide polymorphisms (SNPs) associated with unique pathways, identifying unique druggable targets for each stage.